CD5L Antibody [Unconjugated]

CD5L was detected in immersion fixed paraffin-embedded sections of mouse spleen using Goat Anti-Mouse CD5L Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2834) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Mu
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CD5L Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse CD5L
  Glu22-Val352
  Accession # Q9QWK4
• Specificity: Detects mouse CD5L in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 10% cross-reactivity with recombinant human CD5L is observed and less than 1% cross-reactivity with recombinant mouse CD5 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CD5L
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD5L Antibody [Unconjugated]

• AIM
• API6
• apoptosis inhibitor 6
• CD5 antigen-like (scavenger receptor cysteine rich family)
• CD5 antigen-like
• CD5 molecule-like
• CD5L
• CT-2
• IgM-associated peptide
• PRO229
• Spalpha
• SP-alpha

Background

CD5L (CD5 antigen-like), also known as Sp alpha and AIM, is a 50 kDa secreted glycoprotein that belongs to the SRCR (scavenger receptor cysteine-rich) group B family of proteins. Group B proteins are distinguished by SRCR domains that are encoded by a single exon (1‑3). The human CD5L cDNA encodes a 347 amino acid (aa) precursor that includes a 19 aa signal sequence and three SRCR domains (4, 5). Among group B proteins, CD5L is most closely related to CD5 and CD6, with which it shares 18% and 31% aa sequence identity, respectively. CD5L is upregulated in macrophages at inflammatory sites. It sustains inflammatory reactions by both increasing the phagocytic capacity of macrophages and impeding the apoptosis of local macrophages, NK cells, and T cells (6, 7). Agonists of the LXR and RXR nuclear hormone receptors induce CD5L upregulation in macrophages and reduce macrophage apoptosis (8, 9). Oxidized LDL (which acts through LXR/RXR) is taken up by macrophages, promoting their development into foam cells. The increased level of CD5L protects foam cells from apoptosis but permits more rapid cellular accumulation and atherosclerotic plaque formation (9). In activated B cells, however, the combination of CD5L and TGF-beta inhibits proliferation. The binding of CD5L to splenic B cells is increased following TGF-beta exposure, suggesting that TGF-beta increases the expression or availability of an unidentified CD5L receptor (5, 10). CD5L also functions as a pattern recognition molecule by binding both lipoteichoic acid on Gram positive and lipopolysaccharide on Gram negative bacteria (11). In the thymic cortex, CD5L protects cortical CD4⁺CD8⁺ thymocytes from apoptosis (12). CD5L circulates in the serum in complex with IgM (13).

1. Sarrias, M.R. et al. (2004) Crit. Rev. Immunol. 24:1.
2. Resnick, D. et al. (1994) Trends Biochem. Sci. 19:5.
3. Mukhopadhyay, S. and S. Gordon (2004) Immunobiology 209:39.
4. Gebe, J.A. et al. (1997) J. Biol. Chem. 272:6151.
5. Gebe, J.A. et al. (2000) Immunology. 99:78.
6. Haruta, I. et al. (2001) J. Biol. Chem. 276:22910.
7. Kuwata, K. et al. (2003) Am. J. Pathol. 162:837.
8. Valledor, A.F. et al. (2004) Proc. Natl. Acad. Sci. 101:17813.
9. Arai, S. et al. (2005) Cell Metab. 1:201.
10. Yusa, S. et al. (1999) Eur. J. Immunol. 29:1086.
11. Sarrias, M-R. et al. (2005) J. Biol. Chem. 280:35391.
12. Miyazaki, T. et al. (1999) J. Exp. Med. 189:413.
13. Tissot, J.D. et al. (2002) Electrophoresis 23:1203.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CD5L Antibody (AF2834)(2)

Publications using AF2834

• L Sanchez-Mo, T Paul, C Martori, J Font-Díaz, L Sanjurjo, G Aran, É Téllez, J Blanco, J Carrillo, M Ito, M Tuttolomon, HJ Ditzel, C Fumagalli, G Tapia, J Sidorova, H Masnou, MA Fernández-, JJ Lozano, C Vilaplana, A Rodriguez-, C Armengol, AF Valledor, L Kremer, MR Sarrias Macrophage CD5L is a target for cancer immunotherapy EBioMedicine, 2023-04-11;91(0):104555. 2023-04-11 [PMID: 37054630] (Immunocytochemistry, Mouse)
• Steven R. Shuken, Jarod Rutledge, Tal Iram, Patricia Moran Losada, Edward N. Wilson, Katrin I. Andreasson et al. Limited proteolysis–mass spectrometry reveals aging-associated changes in cerebrospinal fluid protein abundances and structures Nature Aging 2023-02-06 [PMID: 36741774]

Bioinformatics

• Gene Symbol: CD5L
• Uniprot:
  • Q9QWK4()